Patrys Vision - to become the world leader in novel therapeutic approaches for patients with cancer and other diseases, including the broad development of natural human antibody based therapies for the treatment of lung, pancreatic and gastric cancers.

Patrys – the natural human antibody based company

Patrys Limited (ASX: PAB) is an Australian public company committed to the development of novel treatments for cancer and other diseases, including the commercialisation of a unique natural human antibody based therapies for the treatment of lung, pancreatic, gastric and colon cancers.

The company has the world-wide and exclusive rights to technologies that have been developed over 25 collective years of research and development and which uniquely allow for the capture, development and production of natural human antibodies for potential therapeutic applications. The technologies, and resulting deep product pipeline, have achieved positive results in animal studies in the treatment of human lung, pancreatic, gastric and colon cancers.

Patrys also currently benefits from the prior establishment of drug development collaborations with three large pharmaceutical companies.

In addition to its internal drug development projects and existing collaborations, the company has also acquired a substantial preferred equity holding in Acceptys, Inc., an American company developing the platform natural human antibody technology for the treatment of infectious diseases, including Hepatitis C, Hepatitis B, Pneumonia and Staph A.

Patrys' commercial strategy is to blend the internal development of lead product candidates while simultaneously benefiting from partnerships and collaborations aimed at developing additional product candidates from the company's deep product pipeline.